Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

179.67 +1.28 (+0.72%)
Streaming Delayed Price Updated: 12:25 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,402,956
Open 178.41
Bid (Size) 179.61 (6)
Ask (Size) 179.72 (2)
Prev. Close 178.39
Today's Range 177.84 - 179.71
52wk Range 153.58 - 207.32
Shares Outstanding N/A
Dividend Yield 3.45%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Schwab US Dividend Equity ETF Reverses In December: What's Going On?
The Schwab US Dividend Equity ETF has given back more than half of its one-year gains in the last month, with the ETF falling more than 7% in December. Here's a look at what may be plaguing the fund: 
Via Benzinga
Topics ETFs
Is AbbVie Stock a Buy?
Via The Motley Fool

Performance

YTD
+12.42%
+12.42%
1 Month
+1.47%
+1.47%
3 Month
-7.31%
-7.31%
6 Month
+4.01%
+4.01%
1 Year
+16.20%
+16.20%

More News

Read More
2 Excellent Dividend Stocks to Buy on the Dip
Via The Motley Fool
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Via Benzinga
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
Via The Motley Fool
Analyst Scoreboard: 19 Ratings For AbbVie
Via Benzinga
Check Out What Whales Are Doing With ABBV
Via Benzinga
Check Out What Whales Are Doing With ABBV
Via Benzinga
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally
Via The Motley Fool
2 Top Dividend Stocks to Buy and Hold Through 2025 and Beyond
Via The Motley Fool
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back?
Via Investor's Business Daily
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
Via The Motley Fool
Neurocrine Wins FDA Approval For Genetic Disorder Drug
Via Investor's Business Daily
Exposures Product Safety
Spotlight on AbbVie: Analyzing the Surge in Options Activity
Via Benzinga
(ABBV) - Analyzing AbbVie's Short Interest
Via Benzinga
1 Magnificent S&P 500 Dividend Stock Down 14% to Buy and Hold Forever
Via The Motley Fool
Topics Stocks
Exposures US Equities
AbbVie's Early Parkinson's Candidate Hits Primary Goal In Pivotal Late-Stage Study
Via Benzinga
Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts
Via Benzinga
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields
Via Benzinga
3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer
Via The Motley Fool
It’s Been A Tough Month For Healthcare Stocks
Via Talk Markets
Topics ETFs Stocks / Equities
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
Via The Motley Fool
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
Via The Motley Fool
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.